The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spi ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...

GOP Rep. Marjorie Taylor Greene of Georgia, an outspoken COVID-19 vaccine critic, blasted the FDA's green lighting of the mNEXSPIKE as "Not MAHA at all!!!" in a tweet ...

The mNexspike vaccine is supplied as a single-dose prefilled syringe containing 1 dose of 0.2mL. The single 0.2mL dose should be administered at least 3 months after the last dose of COVID-19 vaccine.

The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine ...

The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 4 The FDA has approved Moderna’s next-generation COVID-19 vaccine for ...

The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose – a fifth of the dose of its current COVID-19 vaccine, ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...